1312MO Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: Overall survival data from the first line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (phase II)
| Autor: | Carcereny, E., Felip, E., Majem, M., Doger de Spéville, B., Clay, T.D., Bondarenko, I., Peguero, J., Cobo Dols, M., Forster, M.D., Ursol, G., Kalinka, E., Garcia Ledo, G.M., Vila Martinez, L., Iams, W., Krebs, M.G., Kefas, J., Efthymiadis, K., Perera, S., Mueller, C., Triebel, F. |
|---|---|
| Zdroj: | In Annals of Oncology October 2023 34 Supplement 2:S754-S754 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|